BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6067489)

  • 21. Lack of toxicity of high dose propoxyphene napsylate when used for maintenance treatment of addiction.
    Woody GE; McLellan AT; O'Brien CP; Tennant FS; Mintz J
    Clin Toxicol; 1980 Jun; 16(4):473-8. PubMed ID: 6105935
    [No Abstract]   [Full Text] [Related]  

  • 22. Propoxyphene and congenital malformations.
    Barrow MV; Souder DE
    JAMA; 1971 Sep; 217(11):1551-2. PubMed ID: 5109758
    [No Abstract]   [Full Text] [Related]  

  • 23. Deaths involving propoxyphene. A study of 41 cases over a two-year period.
    Sturner WQ; Garriott JC
    JAMA; 1973 Mar; 223(10):1125-30. PubMed ID: 4739371
    [No Abstract]   [Full Text] [Related]  

  • 24. Sulfonamide-induced hypoglycemia in chronic renal failure.
    Arem R; Garber AJ; Field JB
    Arch Intern Med; 1983 Apr; 143(4):827-9. PubMed ID: 6340631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term comparison of suprofen and propoxyphene in patients with osteoarthritis.
    Salzman RT; Brobyn RD
    Pharmacology; 1983; 27 Suppl 1():55-64. PubMed ID: 6361792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased clinical efficacy of propoxyphene in cigarette smokers.
    Clin Pharmacol Ther; 1973; 14(2):259-63. PubMed ID: 4695386
    [No Abstract]   [Full Text] [Related]  

  • 27. Dextropropoxyphene: withdrawn in the EU. Withdrawn from pharmacies in France.
    Prescrire Int; 2009 Aug; 18(102):166. PubMed ID: 19746528
    [No Abstract]   [Full Text] [Related]  

  • 28. [The risk of hypoglycemia in sulfonylurea therapy].
    Berger W; Koller F
    Helv Med Acta; 1972 Apr; 36(2):228-9. PubMed ID: 5029101
    [No Abstract]   [Full Text] [Related]  

  • 29. The influence of propoxyphene withdrawal on opioid use in veterans.
    Hayes CJ; Hudson TJ; Phillips MM; Bursac Z; Williams JS; Austin MA; Edlund MJ; Martin BC
    Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1180-8. PubMed ID: 26248742
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dextropropoxyphene: withdrawal from the US market requested: harmful drug.
    Prescrire Int; 2009 Aug; 18(102):166-7. PubMed ID: 19746529
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical evaluation of d-propoxyphene napsylate (S-9700) as an anesthetic premedicant].
    Miyazaki M; Okuno Y; Goto S; Kodama H
    Masui; 1972 Mar; 21(3):199-205. PubMed ID: 4555736
    [No Abstract]   [Full Text] [Related]  

  • 32. [Benign recurrent cholestasis following use of propoxyphene (Depronal)].
    Kerst AJ; Strik HP
    Ned Tijdschr Geneeskd; 1979 Sep; 123(36):1570-2. PubMed ID: 481629
    [No Abstract]   [Full Text] [Related]  

  • 33. Dextropropoxyphene: welcome withdrawal from a French hospital's formulary.
    Prescrire Int; 2008 Jun; 17(95):112. PubMed ID: 18629970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA raises safety issues concerning propoxyphene.
    Aschenbrenner DS
    Am J Nurs; 2010 Jan; 110(1):59-60. PubMed ID: 20032671
    [No Abstract]   [Full Text] [Related]  

  • 35. Concentration of propoxyphene in human plasma following oral, intramuscular, and intravenous administration.
    Wolen RL; Gruber CM; Kiplinger GF; Scholz NE
    Toxicol Appl Pharmacol; 1971 Jul; 19(3):480-92. PubMed ID: 4936997
    [No Abstract]   [Full Text] [Related]  

  • 36. Pulmonary arteriole foreign body granulomata associated with angiomatoids resulting from the intravenous injection of oral medications, e. g., propoxyphene hydrochloride (Darvon).
    Butz WC
    J Forensic Sci; 1969 Jul; 14(3):317-26. PubMed ID: 5802944
    [No Abstract]   [Full Text] [Related]  

  • 37. Close vote by FDA advisers favors propoxyphene withdrawal.
    Traynor K
    Am J Health Syst Pharm; 2009 Mar; 66(6):518-20. PubMed ID: 19265176
    [No Abstract]   [Full Text] [Related]  

  • 38. Propoxyphene use and risk for hip fractures in older adults.
    Kamal-Bahl SJ; Stuart BC; Beers MH
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):219-26. PubMed ID: 17062322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catastrophic neurologic signs due to drug interaction: Tegretol and Darvon.
    Oles KS; Mirza W; Penry JK
    Surg Neurol; 1989 Aug; 32(2):144-51. PubMed ID: 2749458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind comparison of namoxyrate and d-propoxyphene: a cooperative clinical trial.
    Cohen A; Corgill DA; Abruzzi W; Ligon CW; DeFelice EA
    J New Drugs; 1966; 6(1):38-44. PubMed ID: 5330694
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.